<DOC>
	<DOCNO>NCT00343564</DOCNO>
	<brief_summary>This study early-phase trial arrange two phase . The Phase I portion dose-escalation study design assess safety , tolerability identify maximum tolerate dose SB-743921 patient Non-Hodgkin Lymphoma Hodgkin Lymphoma . Phase II intend ass activity , safety tolerability SB-743921 patient Indolent Aggressive Non-Hodgkin 's Lymphomas exclusively . The Phase II portion study initiate .</brief_summary>
	<brief_title>A Study SB-743921 Non-Hodgkin Lymphoma Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Phase 1 : Patients evaluable measurable ( MRI CT ) Hodgkin 's Disease NonHodgkin 's Lymphoma . Phase 2 : Patients Measurable NonHodgkin 's Lymphomas ( Indolent Aggressive ) . Patients Indolent NHL must relapse refractory least one prior line therapy ( CHOP , CVP , chlorambucil fludaribine ) . Prior treatment Rituximab require . Patients Aggressive NHL refractory ( relapse ) least one CHOPbased therapy prior treatment Rituximab candidate highdose chemotherapy autologous stem cell transplantation . ECOG performance status 02 Autologous stem cell transplant recipient eligible 100 day elapse since procedure . Exclusion Criteria : Phase 1 : History prior radioimmunotherapy ( Bexxar , Zevalin ) ; These patient ARE permitted Phase 2 trial . Current active malignancy besides NHL , except excise nonmelanoma skin cancer , insitu cervical bladder cancer early stage prostate cancer . Patients leptomeningeal CNS lymphoma Known allergy and/or receipt treatment contraindicate administration GCSF Patients active Hepatitis B C , patient HIV infection . Pregnant breastfeeding female . Previous treatment KSP inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>